Neurotrope Inc (NASDAQ:NTRP) Expected to Post Earnings of -$0.34 Per Share

Analysts expect Neurotrope Inc (NASDAQ:NTRP) to report ($0.34) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Neurotrope’s earnings. Neurotrope posted earnings per share of ($0.47) in the same quarter last year, which indicates a positive year-over-year growth rate of 27.7%. The company is scheduled to report its next quarterly earnings report on Monday, March 9th.

According to Zacks, analysts expect that Neurotrope will report full year earnings of ($1.33) per share for the current financial year. For the next fiscal year, analysts forecast that the business will post earnings of ($1.30) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Neurotrope.

A number of research firms recently issued reports on NTRP. Maxim Group lowered Neurotrope from a “buy” rating to a “hold” rating in a report on Monday, September 9th. Janney Montgomery Scott lowered Neurotrope from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $13.00 to $1.00 in a report on Wednesday, September 11th. Finally, Zacks Investment Research lowered Neurotrope from a “buy” rating to a “hold” rating in a report on Friday, November 1st.

Shares of NTRP stock traded up $0.05 during mid-day trading on Monday, hitting $0.91. 340,500 shares of the stock were exchanged, compared to its average volume of 224,766. The stock’s fifty day simple moving average is $0.73 and its two-hundred day simple moving average is $4.03. The stock has a market capitalization of $11.86 million, a price-to-earnings ratio of -0.66 and a beta of 1.97. Neurotrope has a 12-month low of $0.63 and a 12-month high of $8.40.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NTRP. Virtu Financial LLC purchased a new position in shares of Neurotrope during the third quarter worth about $52,000. Vanguard Group Inc. lifted its position in Neurotrope by 21.7% in the second quarter. Vanguard Group Inc. now owns 266,735 shares of the company’s stock valued at $2,139,000 after purchasing an additional 47,609 shares during the period. BlackRock Inc. lifted its position in Neurotrope by 144.3% in the second quarter. BlackRock Inc. now owns 60,041 shares of the company’s stock valued at $482,000 after purchasing an additional 35,464 shares during the period. Millennium Management LLC acquired a new stake in Neurotrope in the third quarter valued at about $28,000. Finally, NorthRock Partners LLC lifted its position in Neurotrope by 45.5% in the second quarter. NorthRock Partners LLC now owns 104,000 shares of the company’s stock valued at $834,000 after purchasing an additional 32,500 shares during the period. 9.54% of the stock is currently owned by hedge funds and other institutional investors.

About Neurotrope

Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases.

See Also: Bear Market – How and Why They Occur

Get a free copy of the Zacks research report on Neurotrope (NTRP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit